Posted by Michael Wonder on 13 Aug 2024
Introducing Jubbonti and Wyost, the first denosumab biosimilars on the Canadian market
12 August 2024 - Jubbonti and Wyost are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access for patients.
Sandoz Canada today announces the launch of two denosumab biosimilars: Jubbonti and Wyost.
Jubbonti is available in 60 mg/mL solution in single-use pre-filled syringe and is approved for treating osteoporosis and increasing bone mass. The product is expected to be listed on all provincial formularies in the near future.
